Focus: Neuronetics is a medical device company specializing in Transcranial Magnetic Stimulation (TMS) therapy for psychiatric and neurological disorders, with 5,000+ employees and public trading status (STIM ticker).
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Growing — net +19 jobs in 30d
40 jobs added vs 21 removed. Steady team buildout.
Neuronetics offers a rare blend of established device market presence and psychiatric expansion upside, but financial losses and M&A speculation warrant caution for stability-focused candidates.
Help build intelligence for Neuronetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neuronetics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Seasonal Patterns - UBND thành phố Hải Phòng
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Seasonal Patterns UBND thành phố Hải Phòng
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Institutional Buying - Cổng thông tin điện tử tỉnh Lào Cai
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Institutional Buying Cổng thông tin điện tử tỉnh Lào Cai
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Community Driven Stock Picks - Newser
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Community Driven Stock Picks Newser
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Expert Momentum Signals - Newser
Neuronetics (STIM) Stock: Underpriced? (+11.27%) 2026-04-20 - Expert Momentum Signals Newser
Malvern’s Neuronetics Faces Sale Pressure From Top Shareholder - VISTA.Today
Malvern’s Neuronetics Faces Sale Pressure From Top Shareholder VISTA.Today
Malvern’s Neuronetics Announces New CEO as 2025 Revenue Nearly Doubles to $149M - VISTA.Today
Malvern’s Neuronetics Announces New CEO as 2025 Revenue Nearly Doubles to $149M VISTA.Today
Showing 6 of 7 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo